Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CYTK
stocks logo

CYTK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
10.62M
-37.25%
-1.408
+11.73%
19.50M
+1135.07%
-1.523
+12.01%
27.29M
-59.13%
-1.535
+37.05%
Estimates Revision
The market is revising Downward the revenue expectations for Cytokinetics, Incorporated (CYTK) for FY2025, with the revenue forecasts being adjusted by -1.42% over the past three months. During the same period, the stock price has changed by 25.52%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.42%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+12.62%
In Past 3 Month
Stock Price
Go Up
up Image
+25.52%
In Past 3 Month
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 79.15 USD with a low forecast of 41.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 79.15 USD with a low forecast of 41.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 66.540
sliders
Low
41.00
Averages
79.15
High
120.00
Current: 66.540
sliders
Low
41.00
Averages
79.15
High
120.00
RBC Capital
Outperform
maintain
$82 -> $87
2025-11-11
Reason
RBC Capital
Price Target
$82 -> $87
2025-11-11
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Cytokinetics to $87 from $82 and keeps an Outperform rating on the shares ahead of the company's "highly anticipated" launch of aficamten in 2026. The firm is updating its modeling assumptions on opex and revenues to better reflect what early U.S. launch dynamics in 2026 could look like following the December 2025 PDUFA, anchoring to historical competitor data, the analyst tells investors in a research note.
BofA
Jason Zemansky
Neutral
maintain
$62 -> $63
2025-11-06
Reason
BofA
Jason Zemansky
Price Target
$62 -> $63
2025-11-06
maintain
Neutral
Reason
BofA analyst Jason Zemansky raised the firm's price target on Cytokinetics to $63 from $62 and keeps a Neutral rating on the shares. The Q3 report and call were "uneventful" and unlikely to impact the thesis much, says the analyst, who cites adjusted operating expense projections, offset by the change in net cash, for the firm's price target increase.
JPMorgan
Overweight
maintain
$55 -> $70
2025-11-03
Reason
JPMorgan
Price Target
$55 -> $70
2025-11-03
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Cytokinetics to $70 from $55 and keeps an Overweight rating on the shares. The firm upped the price target after revisiting its epidemiology and diagnosis rate assumptions for obstructive and nonobstructive hypertrophic cardiomyopathy. Diagnosis trends indicate nonobstructive hypertrophic cardiomyopathy is growing at a faster rate than obstructive and could account for up to half of the total HCM market over time, the analyst tells investors in a research note.
BofA
Neutral
maintain
$56 -> $62
2025-10-21
Reason
BofA
Price Target
$56 -> $62
2025-10-21
maintain
Neutral
Reason
BofA raised the firm's price target on Cytokinetics to $62 from $56 and keeps a Neutral rating on the shares. After incorporating the latest feedback from key opinion leaders, the firm is "modestly" increasing its aficamten forecasts, the analyst tells investors.
B. Riley
B. Riley
Buy
maintain
$74 -> $80
2025-09-22
Reason
B. Riley
B. Riley
Price Target
$74 -> $80
2025-09-22
maintain
Buy
Reason
B. Riley raised the firm's price target on Cytokinetics to $80 from $74 and keeps a Buy rating on the shares. Cytokinetics is among the firm's top ideas heading into year-end aficamten FDA approval. Management reported positive feedback a from late-cycle FDA meeting focused on final implementation details, with no additional language requests, which ultimately supports the potential for a differentiated REMS program as part of the initial label grant and risk mitigation profile, the analyst tells investors in a research note.
BofA
Neutral
maintain
$45 -> $52
2025-09-04
Reason
BofA
Price Target
$45 -> $52
2025-09-04
maintain
Neutral
Reason
BofA raised the firm's price target on Cytokinetics to $52 from $45 and keeps a Neutral rating on the shares. The ESC conference "was a win for the company," headlined by MAPLE trial data for aficamten, the analyst tells investors. However, while the firm doesn't disagree with the view that aficamten has "solid clinical value," practical headwinds are already slowing uptake in advanced patients for drugs in its class, so the firm says it is "challenging for us to forecast much early-line use."
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cytokinetics Inc (CYTK.O) is -11.16, compared to its 5-year average forward P/E of -9.69. For a more detailed relative valuation and DCF analysis to assess Cytokinetics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.69
Current PE
-11.16
Overvalued PE
-7.26
Undervalued PE
-12.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.72
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-7.00
Undervalued EV/EBITDA
-12.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
182.18
Current PS
0.00
Overvalued PS
379.25
Undervalued PS
-14.89
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 187.9% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 5964.05% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 187.9% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CYTK News & Events

Events Timeline

(ET)
2025-11-17
08:23:07
Cytokinetics backs AHA effort to enhance care for individuals with HCM
select
2025-11-10 (ET)
2025-11-10
07:58:14
Cytokinetics Reveals New Findings from MAPLE-HCM Study
select
2025-11-05 (ET)
2025-11-05
16:02:04
Cytokinetics Announces Q3 Earnings Per Share of $2.55, Exceeding Consensus Estimate of $1.57
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
01:22 AMGlobenewswire
Cytokinetics Faces Shareholder Claims Over Executive Misconduct
  • Shareholder Claims Investigation: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders who purchased shares before December 27, 2023, to seek corporate reforms and fund recovery.
  • FDA Approval Delay: On May 1, 2025, Cytokinetics announced that the FDA extended the review date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the omission of a Risk Evaluation and Mitigation Strategy in the initial filing, causing significant shareholder harm.
  • False Statement Allegations: Executives are accused of misleading investors by stating on March 10, 2025, that the FDA would not convene an advisory committee meeting, leading to incorrect assessments of the company's prospects and negatively impacting stock prices.
  • Severe Market Reaction: These allegations have left Cytokinetics' shareholders facing potential financial losses, severely undermining market confidence in the company's future and possibly leading to further declines in stock value.
[object Object]
Preview
7.0
12-03Globenewswire
Cytokinetics Faces Shareholder Investigation Over Alleged Misstatements
  • Shareholder Investigation Initiated: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders to seek corporate reforms and fund recovery, highlighting potential governance risks within the company.
  • FDA Review Delay: On May 1, 2025, Cytokinetics announced that the FDA extended the review date for aficamten's NDA from September 26, 2025, to December 26, 2025, indicating compliance issues that could undermine future market confidence.
  • Impact of Misstatements: Company executives acknowledged that they submitted the NDA without including a Risk Evaluation and Mitigation Strategy (REMS), leading to misleading statements about the company's prospects, which could result in significant financial harm to shareholders.
  • Potential Legal Consequences: These misleading statements may expose Cytokinetics to lawsuits and liability, further impacting its stock price and market reputation, underscoring deficiencies in the company's transparency and compliance practices.
[object Object]
Preview
7.0
12-01Globenewswire
Crucial Update for Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK), Fortrea Holdings, Inc. (NASDAQ: FTRE), Ibotta, Inc. (NYSE: IBTA), and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Looking into Claims for You

  • Cytokinetics Investigation: Grabar Law Office is investigating claims against Cytokinetics, Inc. for potential breaches of fiduciary duties by its officers and directors, following allegations of misleading statements regarding the FDA's review process for their drug aficamten, which harmed shareholders.

  • Fortrea Holdings Investigation: Shareholders of Fortrea Holdings, Inc. are being investigated for claims of misleading statements about the company's financial prospects and operations, which allegedly inflated their earnings targets and misrepresented the viability of their business model.

  • Ibotta Investigation: Grabar Law Office is looking into claims against Ibotta, Inc. for misleading investors during its IPO regarding the risks associated with its contract with Kroger, which was at-will and could be terminated without notice, potentially impacting the company's revenue.

  • WEBTOON Entertainment Investigation: A class action lawsuit against WEBTOON Entertainment Inc. has survived a motion to dismiss, with allegations that the company misrepresented its Monthly Active Users and failed to disclose adverse trends affecting its business prior to its IPO.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cytokinetics Inc (CYTK) stock price today?

The current price of CYTK is 66.54 USD — it has increased 2.91 % in the last trading day.

arrow icon

What is Cytokinetics Inc (CYTK)'s business?

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

arrow icon

What is the price predicton of CYTK Stock?

Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 79.15 USD with a low forecast of 41.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cytokinetics Inc (CYTK)'s revenue for the last quarter?

Cytokinetics Inc revenue for the last quarter amounts to 1.94M USD, increased 318.14 % YoY.

arrow icon

What is Cytokinetics Inc (CYTK)'s earnings per share (EPS) for the last quarter?

Cytokinetics Inc. EPS for the last quarter amounts to -2.55 USD, increased 87.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cytokinetics Inc (CYTK)'s fundamentals?

The market is revising Downward the revenue expectations for Cytokinetics, Incorporated (CYTK) for FY2025, with the revenue forecasts being adjusted by -1.42% over the past three months. During the same period, the stock price has changed by 25.52%.
arrow icon

How many employees does Cytokinetics Inc (CYTK). have?

Cytokinetics Inc (CYTK) has 498 emplpoyees as of December 05 2025.

arrow icon

What is Cytokinetics Inc (CYTK) market cap?

Today CYTK has the market capitalization of 8.14B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free